A multi-compound dietary supplement to improve the well-being of symptomatic uncomplicated diverticular disease
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
BACKGROUND: Current treatment strategies for symptomatic uncomplicated diverticular disease (SUDD) remain controversial. Nutraceuticals could be potential adjuvant treatments to reduce symptoms and improve Quality of Life (QoL). METHODS: A retrospective analysis of data collected in a real-world clinical setting was performed on SUDD patients with persistent diarrheal symptoms following rifaximin therapy. A synbiotic anti-inflammatory dietary supplement (SADS), containing Lactobacillus rhamnosus GG, Hericium erinaceus, berberine, quercetin, palmitoylethanolamide, and Undaria, was administered daily for one month to evaluate its effectiveness in reducing these symptoms. Outcome measures included daily bowel movement frequency, Abdominal Pain Score, treatment satisfaction, and fecal calprotectin levels, and were evaluated at baseline (T0) and after one month (T1). RESULTS: Data from 54 SUDD patients (mean age: 53.2±11.3 years) were collected. Daily bowel movements significantly decreased after SADS treatment (T1) compared to T0 (2.18±0.8 vs. 3.8±0.7; P
Fields of Study & Subjects
Diverticular Disease and Complications
Gastrointestinal motility and disorders
Inflammatory Bowel Disease
Publication details
- Journal / source
- Minerva Gastroenterology
- Volume
- 72
- Issue
- 2
- Pages
- 169–177
- Publication date
- 30 March 2026
- Language
- EN